Loading...

ABUS ARBUTUS BIOPHARMA CORP Legal Disputes 8-K Filing

RBTS

BS

ARBUTUS BIOPHARMA CORP

(ABUS)

2026 8-K

Shareholder Approvals

Quarterly Results

FDA Fast Track Granted

Financial Results Released

Settlement Agreement

Patent Litigation Update

Court Ruling Update

Patent Decision Update

Lawsuit Presentation

Financial Results Report

Presentation Announcement

Legal Ruling Update

Resignations, Appointments

Termination of Agreement

Financial Statements

Presentation of Research Fi...

Conference Presentations

Management Changes

Financial Results

Patent Litigation

Board Restructuring

Financial Update

Clinical Trial Results

Q3 2024 Results

Clinical Data Presentation

Management Change

Regulation FD Disclosure

Financial Results and Corpo...

Clinical Trial Results

Clinical Trial Results

Shareholder Meeting Approval

Announcement of Abstract Ac...

Financial Results and Corpo...

Retirement of Chief Scienti...

Financial Results and Corpo...

Financial Results

Management Changes

Poster Presentation and Cor...

Financial Results, Workforc...

Retirement and Appointment

Announcement of Data Presen...

Pipeline Updates

Financial Results and Corpo...

Clinical Trial Update

Clinical Trial Results

Announcement of Poster Pres...

Management Changes

Financial Results and Corpo...

Clinical Data Presentation

Announcement of Abstract Ac...

Lawsuit against Pfizer and ...

Preclinical Data Announcement

Financial Results and Corpo...

Resignation of Director

External Links:

On April 15, 2026, Arbutus Biopharma Corp announced that the FDA granted Fast Track designation for their drug imdusiran to treat chronic hepatitis B.

AI Assistant

ARBUTUS BIOPHARMA CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.